R2 민준기 / 정재헌 교수님. Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT)

Slides:



Advertisements
Similar presentations
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Advertisements

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
DAHANCA 16 Planned post-radiation neck dissection vs salvage neck dissection in patients with N2-3 SCC of the head and neck treated with primary radiotherapy.
Intergroup trial CALGB 80101
A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion of Chemotherapy.
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.
INT Translational research in head and neck cancer: preoperative chemotherapy in oral cavity cancer based on disease molecular profiling. Paolo Bossi MSO.
Prepared By : Miss. Sana’a AL-Sulami Teacher Assistant.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, M.D., Ph.D., Christian Domenge,
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
11 One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Joensuu H, Eriksson M, Sundby Hall K, et al.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.
Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Regularly Scheduled Artificial (IV) Hydration among Head and Neck Cancer Patients Undergoing Radiotherapy-based Treatment By Jessica Mooney With special.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, in Patients with.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
R4 박재훈 / F 황인경. Introduction Squamous-cell carcinoma about 30% of NSCLC Treatment for advanced squamous-cell NSCLC docetaxel for secondline.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Empirical versus Preemptive Antifungal Therapy for High-Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial Clinical Infectious Diseases.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
SNDA ETHYOL FOR RADIATION INDUCED XEROSTOMIA.
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Everolimus for Advanced Pancreatic Neuroendocrine Tumors N Engl J Med 2011;364: R4. 박선희 / Prof. 동석호.
12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
Alessandra Gennari, MD PhD
Phase 3 Treatment-Naïve and Treatment-Experienced
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,
Intervista a Lucio Crinò
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
Presentation transcript:

R2 민준기 / 정재헌 교수님

Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT) –Treatment-related oral mucositis (OM) is debilitating decrease nutritional support  Weight loss Infection  treatment interruption  limit Tx efficacy –Reliable and effective drugs targeting OM are lacking

Introduction Keratinocyte growth factor (KGF) –Fibroblast growth factor –Cytoprotective effects on epithelial cells Palifermin –alleviate OM in patients treated with CCRT for hematologic malignancies –Amifostine only comparator compound decreased xerostomia in patients irradiated for head and neck cancer did not protect from OM

Introduction Purpose of this study –Whether Palifermin reduces severe OM in patients undergoing postoperative radiochemotherapy for locally advanced head and neck cancer

Method (Patients) Inclusion criteria –older than 18 years –ECOG performance status of 0 to 2 –pathologically documented stages II to IVB squamous cell carcinoma of the oral cavity, oropharynx,hypopharynx, or larynx –expected to receive at least 50 Gy in oral or oropharyngeal mucosa

Method (Patients) Exclusion criteria –tumors of the lips, paranasal sinuses, salivary glands, or unknown primary site –metastatic disease –history of pancreatitis within the last year –prior radiation to the head and neck region or prior chemotherapy –previous treatment of keratinocyte growth factors

Method (Study Design) Double-blind, randomized, placebo-controlled trial Patients were enrolled between – ~ Conducted at 38 centers –in Australia, Austria, Canada, France, Germany, Italy, Spain, and the United Kingdom

Method (Study Design) Initially, patients were allocated to three arms –Palifermin (180mcg/kg/wk) throughout radiochemotherapy –Palifermin (180mcg/kg/wk) for four doses and then placebo throughout the remainder of radiochemotherapy –Placebo throughout radiochemotherapy –One serious adverse event of respiratory insufficiency was reported 120mcg/kg/wk

Method (Efficacy and Safety End Points) The primary efficacy end point –incidence of severe OM (WHO grade 3 or 4)

Method (Efficacy and Safety End Points) Secondary efficacy end points –Duration of and time to onset of severe OM –xerostomia grade 2 at month 4 –Average mouth and throat soreness (MTS) scores –Incidence of treatment breaks –Incidence of cisplatin delays –Total dose of opioids

Method (Efficacy and Safety End Points) Safety end points –incidence of adverse events and laboratory abnormalities. –disease progression –time to disease progression –incidence of second primary tumors and other malignancies –overall survival

Method (Statistical Analysis) Efficacy analysis –intention to treat Treatment arms comparision –Cochran-Mantel-Haenszel methods Time to onset of an event, progression- free survival, and overall survival –Kaplan-Meier method

Results Palifermin (120g/kg/wk) for four doses and then placebo throughout the remainder of radiochemotherapy (n=38)  slow enrollment, Halted

Baseline patient characteristics

Results (Efficacy) <

< < > 67% 51% 32days 45days

Results (Safety end points) Palifemin > Placebo –dysphagia (35% and 21%) –diarrhea (12% and 5%) –asthenia (14% and 8%) –back pain(6%and 1%) –headache(10%and 4%) –abdominal pain(8%and 2%) Palifemin < Placebo –dehydration (6% and 14%) –leukopenia (13% and 21%) –insomnia (5% and 13%) –fatigue (8% and 15%) –mucosal inflammation (4% and 11%) Adverse events with a difference in incidence of at least 5%

Results (Safety end points) Overall survival and progression-free survival were similar 46 deaths (23deaths [25%] in each treatment arm) Disease recurred in 25 patients (27%)and 22 patients(24%)

Conclusion Palifermin reduced the occurrence of severe oral mucositis in patients with head and neck cancer undergoing postoperative radiochemotherap y.

Discussion (30) (26) Missing data (grade 2) Sample size was chosen only for the primary end point reduced the incidence of severe OM  Clinical relevance ? Innovative administration schedules of the compound and its integration into modern radiation treatment techniques, may additionally elaborate the clinical relevance of our findings